NCT06233916View on ClinicalTrials.gov

Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

January 3, 2024

Study Completion Date

January 10, 2024

Conditions
Mass Balance Study
Interventions
DRUG

[14C] D-1553

\[14C\] D-1553 (approximately 400 mg/80 μCi)

Trial Locations (1)

Unknown

beijing Gobroad Boren Hospital, Beijing

Sponsors
All Listed Sponsors
lead

InventisBio Co., Ltd

INDUSTRY